Orphazyme's creditors left without real options

The creditors of embattled biotech firm Orphazyme find themselves between a rock and hard place: There’ll be no money left if they reject a proposed restructuring plan, but if they do that, there will be no company to save.
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Uncertainty continues to surround Orphazyme’s future, even after the proposal of a restructuring plan by the Danish biotech company’s leadership and the restructuring administrator, Gorrissen Federspiel’s John Sommer Schmidt.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading